33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

• Nicole Zhang,
• Leylah Drusbosky,
• Jiemin Liao,
• Bruna Pellini,
• Sean Gordon,
• Reagan Barnett,
• Katie Quinn,
• Sara Wienke,
• Martina Lefterova,
• Lauren Lawrence,
• Lesli Kiedrowski,
• Ross Eppler,
• Justin Odegaard,
• Han-Yu Chuang

Affiliations

Nicole Zhang

The Valley Foundation School of Nursing, San Jose State University, San Jose, California, USA

Leylah Drusbosky

NantHealth Inc, Culver City, California, USA

Jiemin Liao

2Singapore Eye Research Institute, Singapore, Singapore

Bruna Pellini

1Moffitt Cancer Center, Tampa, FL, USA

Sean Gordon

1Guardant Health, Inc., Redwood City, CA, USA

Reagan Barnett

1Guardant Health, Inc., Redwood City, CA, USA

Katie Quinn

1Guardant Health, Inc., Redwood City, CA, USA

Sara Wienke

1Guardant Health, Inc., Redwood City, CA, USA

Martina Lefterova

1Guardant Health, Inc., Redwood City, CA, USA

Lauren Lawrence

1Guardant Health, Inc., Redwood City, CA, USA

Lesli Kiedrowski

1Guardant Health, Inc., Redwood City, CA, USA

Ross Eppler

1Guardant Health, Inc., Redwood City, CA, USA

Justin Odegaard

1Guardant Health, Inc., Redwood City, CA, USA

Han-Yu Chuang

1Guardant Health, Inc., Redwood City, CA, USA